Drug Approval | July 14, 2023
Lupin receives approval from USFDA for Chlorpromazine Hydrochloride Tablets USP
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Approval to dramatically change CAR-T therapies landscape
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India)
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This product will be manufactured at Lupin's Pithampur facility in India
Subscribe To Our Newsletter & Stay Updated
